CytomX Therapeutics, Inc.
CTMX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $87 | $114 | $105 | $278 |
| - Cash | $38 | $17 | $194 | $206 |
| + Debt | $9 | $14 | $18 | $18 |
| Enterprise Value | $58 | $111 | -$70 | $90 |
| Revenue | $138 | $101 | $53 | $37 |
| % Growth | 36.4% | 90.4% | 42.5% | – |
| Gross Profit | $138 | $101 | $53 | $37 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $27 | -$4 | -$99 | -$113 |
| % Margin | 19.4% | -4.3% | -186% | -303.8% |
| Net Income | $32 | -$1 | -$99 | -$116 |
| % Margin | 23.1% | -0.6% | -186.8% | -310.5% |
| EPS Diluted | 0.38 | -0.008 | -1.48 | -1.26 |
| % Growth | 5,035.1% | 99.5% | -17.5% | – |
| Operating Cash Flow | -$86 | -$56 | -$111 | -$119 |
| Capital Expenditures | -$0 | -$1 | -$2 | -$2 |
| Free Cash Flow | -$87 | -$57 | -$113 | -$121 |